Research results on mix-and-match vaccinations published

Credit: Unsplash / CC0 public domain

Significant international interest arose in early June when Martina Sester, a professor of immunology at the University of Saarland, published a preprint of a study on the combination of different types of COVID-19 vaccines. After a rigorous peer review process, the research results were published in the journal. Nature Medicine. The results have also been taken up by the German Standing Committee for Vaccination (STIKO) and currently recommend mixed vaccination for adults, including adults over the age of 60. A research team led by Martina Sester found that people vaccinated with AstraZeneca as the first dose and BioNTech vaccine as the second dose had significantly stronger immunity than those vaccinated with the AstraZeneca vaccine in both cases. Found to show a response.

The study aimed at determining the strength of Immune response In 216 individuals two weeks after they completed their vaccination series. All subjects were vaccinated during the spring by vocational medical officers at the Saarland University Medical Center in Homburg. Part of the study cohort received two doses of AstraZeneca. vaccination Or two doses of BioNTech / Pfizer vaccine. The remaining subjects were vaccinated once with each vaccine every 9-12 weeks, a method known as heterologous prime boost vaccination (also known as “mix and match” vaccination). Several other members of the test cohort were vaccinated twice with the Moderna vaccine or with a combination of the AstraZeneca and Moderna vaccines.

“In March, the Standing Committee for Vaccination had to recommend a heterologous vaccination regimen without having relevant clinical trial data at hand, so such an analysis is urgently needed from our laboratory. In addition to examining the number of vaccinated coronavirus antibodies, subjects were created and the effectiveness of the neutralizing antibody was determined, which is how much the antibody protects cells from viral infections. You can see how good it is, “explains Martina Sester, a professor of transplantation and infectious immunology at the University of Sarland.

Analysis of antibody production levels showed that the combination of AstraZeneca / BioNTech vaccine or double dose of BioNTech was significantly more effective than double dose of AstraZeneca vaccine. The team found that antibody levels in the blood were about 10 times higher than those who received the AstraZeneca / BioNTech combination or BioNTech double vaccination. “When we examined the neutralizing antibodies, we found that the combination strategy actually gave slightly better results than those achieved with the two doses of BioNTech,” said Martina Sester. Sester’s research team also looked at two different types of T. cell— —White blood cells It plays an important role in the body’s immune system. Helper T cells have many functions, including activating antibody production. The role of killer T cells is to destroy virus-infected cells. Killer T cells are especially important in preventing serious COVID-19 illness and hospitalization.

Both the AstraZeneca / BioNTech vaccine combination and the two BioNTech vaccinations were substantially more effective in producing both types of T cells. Killer T cell production was most pronounced in heterologous vaccinated subjects, reflecting the findings of neutralizing antibodies. “This provides very impressive evidence that two doses of AstraZeneca vaccine cannot mobilize the body’s immune response as strongly as the other two vaccination regimens. However, this provides two doses of AstraZeneca. The level of protection against the virus is inadequate for those who have received it. Successful clinical trials and vaccination campaigns in other countries show the high level of efficacy of the AstraZeneca vaccine, but it is AstraZeneca. It shows that the second dose of is not able to elicit the full potential, which is actually included in this vaccine, “explains immunology expert Martina Sester.

The research team was amazed at how clear the results were. “This is why we wanted to share these findings with more people as soon as possible, rather than waiting for the entire academic peer review process to finish,” explains Professor Sester. Before publishing the findings, researchers evaluated the data in terms of participants’ gender and age to determine which vaccine combination caused the most side effects. “We are currently considering whether to adopt a mixed-and-match approach when giving a third booster shot to an immunocompromised person. These often address existing conditions with weakened immune defenses. An individual who has, who is taking certain medications and who can benefit from booster shots to develop the widest possible immune response, “explains Martina Sester.

Canada: Pfizer, Moderna prefers second dose following AstraZeneca

For more information:
Tina Schmidt et al, Heterologous ChAdOx1 nCoV-19 / mRNA Vaccination Immunogenicity and Responsibility, Nature medicine (2021). DOI: 10.1038 / s41591-021-01464-w

Quote: Published results of the mixed and match vaccination survey (July 28, 2021) can be found at Acquired on July 28, 2021.

This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.

Research results on mix-and-match vaccinations published Source link Research results on mix-and-match vaccinations published

Related Articles

Back to top button